Risks in new drug development: Approval success rates for investigational drugs

被引：300
作者：
DiMasi, JA [1 ]
机构：
[1] Tufts Univ, Tufts Ctr Study Drug Dev, Boston, MA 02111 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2001年 / 69卷 / 05期
关键词：
D O I：
10.1067/mcp.2001.115446
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：297 / 307
页数：11
相关论文
共 24 条
[1]   BIOPHARMACEUTICALS AND CONVENTIONAL DRUGS - CLINICAL SUCCESS RATES [J].
BIENZTADMOR, B ;
DICERBO, PA ;
TADMOR, G ;
LASAGNA, L .
BIO-TECHNOLOGY, 1992, 10 (05) :521-525
[2]  
COX C, 1978, UNPUB TECHNOLOGICAL
[3]  
Cox D. R., 1984, ANAL SURVIVAL DATA
[4]   RESEARCH-AND-DEVELOPMENT COSTS FOR NEW DRUGS BY THERAPEUTIC CATEGORY - A STUDY OF THE UNITED-STATES PHARMACEUTICAL-INDUSTRY [J].
DIMASI, JA ;
HANSEN, RW ;
GRABOWSKI, HG ;
LASAGNA, L .
PHARMACOECONOMICS, 1995, 7 (02) :152-169
[5]   NEW DRUG DEVELOPMENT IN THE UNITED-STATES FROM 1963 TO 1992 [J].
DIMASI, JA ;
SEIBRING, MA ;
LASAGNA, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (06) :609-622
[6]   SUCCESS RATES FOR NEW DRUGS ENTERING CLINICAL-TESTING IN THE UNITED-STATES [J].
DIMASI, JA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) :1-14
[7]   COST OF INNOVATION IN THE PHARMACEUTICAL-INDUSTRY [J].
DIMASI, JA ;
HANSEN, RW ;
GRABOWSKI, HG ;
LASAGNA, L .
JOURNAL OF HEALTH ECONOMICS, 1991, 10 (02) :107-142
[8]   NEW DRUG DEVELOPMENT IN THE UNITED-STATES FROM 1963 TO 1990 [J].
DIMASI, JA ;
BRYANT, NR ;
LASAGNA, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (05) :471-486
[9]  
DiMasi JA, 2000, DRUG INF J, V34, P1169, DOI 10.1177/009286150003400425
[10]  
DiMasi JA., 1995, INT J ECON BUS, V2, P201, DOI [10.1080/758519309, DOI 10.1080/758519309]
123